Shikari® (S-ATNAT) Anti-Natalizumab ELISA w/confirmation
NAT-QNS-TYS
Enzyme immunoassay for the quantitative determination (screening) of antibodies to Natalizumab (TYSABRI®) in serum and plasma with confirmation.
This kit has been especially developed for the quantitative determination of antibodies to natalizumab in serum and plasma samples.
The Matriks Biotek Antibody to Natalizumab ELISA Kit can be efficiently used for monitoring anti-Natalizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Natalizumab antibodies. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 5 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 1,87 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
